Drug Trial Radar · NCT05294458
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Mar 28, 2022
Primary completion
Sep 12, 2022
Study completion Sep 12, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Quotient Sciences
- First posted
- Mar 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease. This healthy volunteer study will try to identify how two different concentrations of cotadutide are taken up by the body when dosed under the skin (subcutaneous injection). The study will also try to identify the absolute bioavailability of cotadutide (amount taken up by the body when dosed under the skin compared to an injection directly into the vein (intravenous)). This is a single-part, three-period study taking place at one non-NHS site in the UK and will involve 12 male and female (non-pregnant/non-lactating) volunteers aged 18-55. For each study period, on Day 1 volunteers will receive cotadutide as either a subcutaneous injection (into the stomach) or an intravenous injection following an overnight fast of at least 10 hours. The subcutaneous injections will be given as either a 1 mg/ml or 5 mg/ml concentration. The intravenous injection will be given as a 0.1 mg/ml concentration. Volunteers will be discharged on Day 4 and there will be a washout period of 7 days between dosing. Blood samples will be taken at regular intervals for pharmacokinetics and safety assessments from Day -1 to discharge. Volunteers will need to return for a follow up visit 28 (±2) days post-first dose for provisional of an anti-drug antibody sample and to ensure wellbeing
Conditions
- Non-alcoholic Steatohepatitis
- Type 2 Diabetes Mellitus (T2DM)
- Chronic Kidney Disease
Interventions
cotadutide solution for injectionDrug
cotadutide solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute bioavailability of the high and the low concentration cotadutide SC formulationsTime frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
- Maximum observed concentration (cmax)Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
- Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted stateTime frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
- Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted stateTime frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Ruddington, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.